CBD claims use experience, case studies; little clinical research – The Leaf Online

Many people have heard credible stories about people who benefit from cannabidiol (CBD) therapies and protections. Most of those reports are “anecdotal,” meaning individual patient case studies that are not part of a clinical study.

Hence, a team of researchers affiliated with King’s College in London decided to look into the situation. They assessed the scientific basis for the safety and clinical efficacy claims of various hemp-derived CBD products commercially marketed over-the-counter (OTC).

According to a literature review published in the journal Therapeutic Advancements in Psychopharmacology, there is little clinical data to support the therapeutic use of such products. Likewise, inaccurate label information makes it difficult to standardize beneficial dosages.

Voters want oversight on CBD products

Researchers reported that the contents of OTC (over-the-counter) CBD products are generally “of variable quality” – a finding that is consistent with numerous prior analyses, such as those herehere and here.

delivery truck leaf CBD cannabidio cannabinoid transportation distribution

Authors further reported that most OTC products contain amounts of CBD that are well below the doses associated with therapeutic benefits in controlled clinical trials.

“Although there is enormous consumer interest in CBD, there is little evidence that OTC preparations have significant pharmacological activity or provide health benefits,” they concluded. “[C]ontrolled trials of OTC preparations are needed to address this issue. There is also a need for more accurate labelling and advertising of OTC CBD products.”

Survey data compiled earlier this year by the National Consumers League reported that more than eight in ten US voters desire greater federal regulatory oversight over the labeling and marketing of commercially available CBD products.

FDA ‘actively evaluating’ what to do

Regulators at the US Food and Drug Administration in March informed members of Congress that it “is actively evaluating what and how much data would be sufficient to support a conclusion that CBD can be safely allowed in dietary supplements under certain conditions.”

At that time, the agency reiterated its longstanding position that the majority of OTC CBD-infused products are marketed in a manner that is inconsistent with the Food, Drug & Cosmetics Act.

Full text of the study, “Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products,” appears in Therapeutic Advancements in Psychopharmacology. Additional information is available from the NORML fact sheet, “FAQs About Cannabidiol.”



Also, Check out our Top 50 CBD E Juices in 2020


Related Products



This post was originally published on this site

Leave a Reply

%d bloggers like this: